α-葡萄糖苷酶抑制剂市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

α-葡萄糖苷酶抑制剂市场按药物和地理划分

市场快照

alpha-glucosidase inhibitors market Overview
Study Period: 2016-2027
Base Year: 2021
Fastest Growing Market: Middle East and Africa
Largest Market: Asia Pacific
CAGR: 0 %
alpha-glucosidase inhibitors market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

  • 全球 α-葡萄糖苷酶抑制剂市场在 2018 年的收入为 40.69 亿美元,预计在 2019-2024 年的预测期内将以 2% 的复合年增长率增长。
  • α-葡萄糖苷酶抑制剂(AGI)的增长适中,因为它主要被认为是二线单药治疗或与其他一线治疗药物联合使用。
  • 增长的主要驱动力主要是在更多的碳水化合物消费地区。由于碳水化合物消费量高,中国和印度的市场价值最高,其次是北美(加拿大和美国)。

报告范围

市场按药物和地理划分 - 增长、趋势和预测(2019 - 2024 年)

Drug
Alpha-glucosidase Inhibitors (Value and Volume 2012-2024)
Alpha-glucosidase Inhibitors
Geography
North America
United States (Value and Volume 2012-2024)
Canada (Value and Volume 2012-2024)
Rest of North America (Value and Volume 2012-2024)
Europe
France (Value and Volume 2012-2024)
Germany (Value and Volume 2012-2024)
Italy (Value and Volume 2012-2024)
Spain (Value and Volume 2012-2024)
United Kingdom (Value and Volume 2012-2024)
Russia (Value and Volume 2012-2024)
Rest of Europe (Value and Volume 2012-2024)
Latin America
Mexico (Value and Volume 2012-2024)
Brazil (Value and Volume 2012-2024)
Rest of Latin America (Value and Volume 2012-2024)
Asia-Pacific
Japan (Value and Volume 2012-2024)
South Korea (Value and Volume 2012-2024)
China (Value and Volume 2012-2024)
India (Value and Volume 2012-2024)
Australia (Value and Volume 2012-2024)
Vietnam (Value and Volume 2012-2024)
Malaysia (Value and Volume 2012-2024)
Indonesia (Value and Volume 2012-2024)
Philippines (Value and Volume 2012-2024)
Thailand (Value and Volume 2012-2024)
Rest of Asia Pacific (Value and Volume 2012-2024)
Middle East and Africa
Saudi Arabia (Value and Volume 2012-2024)
Iran (Value and Volume 2012-2024)
Egypt (Value and Volume 2012-2024)
Oman (Value and Volume 2012-2024)
South Africa (Value and Volume 2012-2024)
Rest of Middle and Africa (Value and Volume 2012-2024)

Report scope can be customized per your requirements. Click here.

主要市场趋势

阿卡波糖是目前可用的其他两种药物中最广泛使用的处方药。

  • 阿卡波糖是目前可用的三种(阿卡波糖、米格列醇和伏格列波糖)α-葡萄糖苷酶抑制剂中最广泛使用的一种,多年来一直用于治疗高血糖症。
  • 阿卡波糖非全身性地减缓碳水化合物的消化并降低餐后血糖 (PPG) 的高水平——这是 2 型糖尿病 (T2DM) 早期病程中的重要表现,也是实现血糖控制的关键目标。
  • 患者在每次主餐开始时服用这些药物。AGI 不会引起低血糖事件或其他危及生命的事件,即使是过量服用,也不会导致体重增加。
  • 尽管大量研究显示阿卡波糖作为一线、二线和三线治疗选择的有益效果,但由于认为某些种族和地区群体的疗效有限,这种药物的处方在世界范围内有所不同。
  • 然而,当以推荐剂量(即,通常每天 3 次 100 mg 阿卡波糖)使用时,AGI 经常引起稀便和肠胃胀气。
  • 由于这些影响与剂量有关,因此建议以低剂量开始治疗,并逐渐增加剂量。稀便的副作用可能对便秘患者有用。
alpha-glucosidase inhibitors market Key Trends

亚太地区在 α-葡萄糖苷酶市场占有最高的市场份额。

  • 亚太地区在 2018 年占据超过 50% 的市场份额。中国正面临世界上最大的糖尿病流行病,约 11% 的人口患有代谢性疾病,而近 36% 的人口处于糖尿病前期。
  • 2018年,中国在亚太地区α-葡萄糖苷酶市场占有最大份额,原因是该国患者人数众多且患病率高。 
alpha-glucosidase inhibitors market Growth by Region

竞争格局

所研究的市场高度分散在每个地区的许多本地参与者中。由于该地区特别是中国和印度有大量仿制药,亚太地区在 2018 年的市场份额最高。 

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Drug

      1. 5.1.1 Alpha-glucosidase Inhibitors (Value and Volume 2012-2024)

        1. 5.1.1.1 Alpha-glucosidase Inhibitors

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume 2012-2024)

        2. 5.2.1.2 Canada (Value and Volume 2012-2024)

        3. 5.2.1.3 Rest of North America (Value and Volume 2012-2024)

      2. 5.2.2 Europe

        1. 5.2.2.1 France (Value and Volume 2012-2024)

        2. 5.2.2.2 Germany (Value and Volume 2012-2024)

        3. 5.2.2.3 Italy (Value and Volume 2012-2024)

        4. 5.2.2.4 Spain (Value and Volume 2012-2024)

        5. 5.2.2.5 United Kingdom (Value and Volume 2012-2024)

        6. 5.2.2.6 Russia (Value and Volume 2012-2024)

        7. 5.2.2.7 Rest of Europe (Value and Volume 2012-2024)

      3. 5.2.3 Latin America

        1. 5.2.3.1 Mexico (Value and Volume 2012-2024)

        2. 5.2.3.2 Brazil (Value and Volume 2012-2024)

        3. 5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)

      4. 5.2.4 Asia-Pacific

        1. 5.2.4.1 Japan (Value and Volume 2012-2024)

        2. 5.2.4.2 South Korea (Value and Volume 2012-2024)

        3. 5.2.4.3 China (Value and Volume 2012-2024)

        4. 5.2.4.4 India (Value and Volume 2012-2024)

        5. 5.2.4.5 Australia (Value and Volume 2012-2024)

        6. 5.2.4.6 Vietnam (Value and Volume 2012-2024)

        7. 5.2.4.7 Malaysia (Value and Volume 2012-2024)

        8. 5.2.4.8 Indonesia (Value and Volume 2012-2024)

        9. 5.2.4.9 Philippines (Value and Volume 2012-2024)

        10. 5.2.4.10 Thailand (Value and Volume 2012-2024)

        11. 5.2.4.11 Rest of Asia Pacific (Value and Volume 2012-2024)

      5. 5.2.5 Middle East and Africa

        1. 5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)

        2. 5.2.5.2 Iran (Value and Volume 2012-2024)

        3. 5.2.5.3 Egypt (Value and Volume 2012-2024)

        4. 5.2.5.4 Oman (Value and Volume 2012-2024)

        5. 5.2.5.5 South Africa (Value and Volume 2012-2024)

        6. 5.2.5.6 Rest of Middle and Africa (Value and Volume 2012-2024)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes population (2012-2024)

    2. 6.2 Type-2 Diabetes population (2012-2024)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Bayer pharma

      2. 7.1.2 Takeda

      3. 7.1.3 Pfizer

      4. 7.1.4 Glenmark pharma

      5. 7.1.5 Sun pharma

      6. 7.1.6 Torrent

      7. 7.1.7 Unichem

      8. 7.1.8 Hexalag

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Alpha-glucosidase Inhibitors Market market is studied from 2016 - 2027.

The Alpha-glucosidase Inhibitors Market is growing at a CAGR of 0% over the next 5 years.

Middle East and Africa is growing at the highest CAGR over 2021- 2026.

Asia Pacific holds highest share in 2021.

Sun Pharma, Bayer, Pfizer, Takeda are the major companies operating in Alpha-glucosidase Inhibitors Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!